ANDROCUR TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CYPROTERONE ACETATE

Disponible depuis:

BAYER INC

Code ATC:

G03HA01

DCI (Dénomination commune internationale):

CYPROTERONE

Dosage:

50MG

forme pharmaceutique:

TABLET

Composition:

CYPROTERONE ACETATE 50MG

Mode d'administration:

ORAL

Unités en paquet:

60

Type d'ordonnance:

Prescription

Domaine thérapeutique:

OTHER MISCELLANEOUS THERAPEUTIC AGENTS

Descriptif du produit:

Active ingredient group (AIG) number: 0116806001; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2007-03-21

Résumé des caractéristiques du produit

_ANDROCUR Product Monograph_
Page 1 of 32
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ANDROCUR
®
cyproterone acetate tablets
50 mg
PR
ANDROCUR
® DEPOT
Cyproterone acetate injection
100 mg/mL
Antiandrogen
Bayer Inc.
2920 Matheson Blvd East,
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Initial Approval:
April 26, 1985
Date of Revision:
May 13, 2021
Submission Control No: 245903
©
2021, Bayer Inc.
® TM see www.bayer.ca/tm-mc.
_ANDROCUR Product Monograph_
Page 2 of 32
Sections or subsections that are not applicable at the time of
authorization are not listed.
TABLE OF CONTENTS ...................................................................................................................2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................................................................
3
1.
INDICATIONS
................................................................................................................................................................
3
2.
CONTRAINDICATIONS
.................................................................................................................................................
3
3.
SERIOUS
WARNINGS
AND
PRECAUTIONS
.................................................................................................................
3
4.
DOSAGE
AND
ADMINISTRATION................................................................................................................................
3
4.1 Dosing Considerations
..........................................................................................................................................
3
4.2 Recommended Dose and Dosage
Adjustment....................................................................................................
3
4.3 Reconstitution
.......................................................................................................................................................
4
4.4 Administration
.........